Redefining approaches to vascular surgery, Bypass Solutions has developed a pioneering minimally invasive procedure to perform suture-less and clamp-less bypasses for long arterial occlusions. This groundbreaking approach offers an alternative to traditional open surgical bypasses with reduced patient recovery times and lowered risk of complications associated with minimally invasive procedures. By merging the benefits of both techniques, it significantly improves patient outcomes while reducing the length of hospital stays.
Our portfolio
Bypass Solutions
Cagent Vascular
Tackling one of the deadliest health challenges, Cagent Vascular addresses the challenges of atherosclerotic cardiovascular disease by advancing the treatment of plaque buildup in arteries. Its novel serration balloon technology, “The Serranator”, uses a balloon with tiny, serrated edges to gently create small, precise grooves in the arterial wall, facilitating the opening of blockages, expansion of blood vessels and improving blood flow. By working at lower inflation pressures, this approach achieves more effective vessel expansion while minimizing barotrauma. Initially focused on treating diseased arteries in the leg, this platform technology has the potential for application in other vascular beds like coronary and dialysis access.
CorFlow Therapeutics
CorFlow Therapeutics is advancing heart attack recovery care with its Controlled Flow Infusion System. This system addresses a significant challenge in cardiovascular treatment: microvascular obstructions that occur after heart attacks, which can prevent proper blood flow to the heart muscle, often going undetected in standard procedures. These obstructions can slow recovery, increase the risk of future heart complications, and worsen patient outcomes. CorFlow’s technology provides real-time diagnosis and potential for targeted treatment of these obstructions during percutaneous coronary interventions (PCIs), potentially improving blood flow to the smallest vessels of the heart and enhancing long-term recovery while reducing heart failure risk.
CorWave
Inspired by the natural efficiency of the human heart, CorWave is transforming the field of circulatory support with its wave membrane technology. At the heart of CorWave’s innovation lies its patented wave membrane technology, which mimics the natural pumping action of the human heart. Unlike traditional rotary pump LVADs, CorWave’s devices—CorWave LVAD and CorWave Nemo—deliver blood flow that closely resembles the body’s physiological patterns, reducing complications like blood cell damage and clotting.
Endovascular Engineering (E2)
E2 is reimagining the approach to pulmonary embolism treatment with the Hēlo thrombectomy system, which removes clots in a single pass using a patented dual-action mechanism. Combining aspiration with mechanical clot disruption, the Hēlo system offers the agility of a low-profile catheter and the power of a large-bore device, combined with a system of minimizing blood loss during the procedure. With its focus on cutting-edge engineering, E2 is setting a new standard in endovascular care for acute pulmonary embolism.
Fastwave Medical
FastWave Medical is at the forefront in addressing one of the most challenging cardiovascular conditions: calcium buildup in arteries, which can severely limit blood flow and increase the risk of heart attacks and strokes. Using their next-generation Intravascular Lithotripsy (IVL) systems, FastWave is developing both electric and laser IVL technologies, each designed to safely and effectively break down hardened calcium deposits in both coronary and peripheral arteries. With improved usability, enhanced balloon catheter performance, and increased emitter durability in its IVL systems, FastWave is addressing current limitations. These improvements allow clinicians to perform procedures with greater ease, reliability, and efficiency. This leads to better patient outcomes and fewer complications during interventions.
Hepta Medical
Hepta Medical is transforming the treatment of early-stage lung and liver cancer with its ablation catheter, offering real-time temperature monitoring to ensure precise and targeted ablation of pulmonary and liver nodules. Current treatments often lack the precision needed to minimize damage to surrounding healthy lung tissue, but Hepta’s catheter allows doctors to control and adjust the ablation process in real time. This approach leads to more effective nodule destruction with fewer side effects, improving both the accuracy of cancer treatments and the quality of life for patients.
LimFlow (Acquired by Inari Medical in November 2023)
Chronic Limb-Threatening Ischemia (CLTI) manifests as non-healing wounds and gangrene. This debilitating condition often results in major amputations, drastically affecting patients’ quality of life. Among the most challenging cases is a subset known as “no Option CLTI”, where current treatment approaches fail, invariably leading to amputation and morbidity. LimFlow offers a revolutionary lifeline for these patients with its Percutaneous Deep Vein Arterialization (pDVA) System. This minimally invasive procedure bypasses blocked leg arteries by rerouting oxygenated blood into the veins, restoring circulation to the foot. The LimFlow System has demonstrated remarkable success in improving quality of life by helping patients avoid major amputations and promoting faster wound healing. The system’s efficacy was validated in LimFlow’s US Pivotal study, PROMISE II, published in the New England Journal of Medicine in March 2023. The study’s success culminated in FDA Pre-Market Approval in September 2023, setting a new standard of care for CLTI patients. LimFlow’s innovation gained further recognition when the company was acquired by Inari Medical in November 2023.
Mercator MedSystems
Mercator MedSystems is transforming drug delivery in the treatment of Peripheral Artery Disease (PAD) and Deep Vein Thrombosis (DVT). The innovative Bullfrog® catheter system uses a tiny, sheathed microneedle to deliver therapeutic agents directly across blood vessel walls into surrounding tissue. By targeting diseased areas with pinpoint accuracy, it aims to efficiently deliver and control the dosage of anti-restenotic drugs administered, helping to reduce restenosis and narrowing of blood vessels inherent after vascular procedures.
Pedra Technology
The Xauron™ Perfusion System is the first technology capable of real-time, non-invasive monitoring of foot tissue perfusion during peripheral vascular procedures. Xauron™ provides clinicians with insights into the effectiveness of an angioplasty procedure and is potentially an invaluable adjunct to monitor tissue perfusion.
PICS Therapeutics
PICS Therapeutics’ next-generation cardiac assist device is transforming early-stage heart failure treatment with its minimally invasive design. Offering targeted support for the heart and kidneys, it addresses conditions like acute heart failure and cardio-renal syndrome while minimizing blood damage and brain injury. With advanced nano-engineering and unique anatomical placement, the device ensures reliability and easy implantation, helping patients recover faster and improve their quality of life.
Protexa Endovascular
Protexa Endovascular addresses a critical risk in Peripheral Artery Disease (PAD) interventions where the release of embolic particles during PAD interventions can block smaller vessels, leading to further complications. The Protexa Guardian Catheter is designed to be compatible with all existing interventional devices, offering the first lower extremity proximal embolic protection solution. It captures these harmful particles as they are released during a procedure, preventing them from traveling to other parts of the body and causing blockages. This protection helps safeguard the microcirculation, reducing the risk of embolization-related complications. By integrating seamlessly with existing endovascular procedures, the Protexa Guardian Catheter adds a crucial layer of safety, enhancing patient outcomes in PAD treatments.
R3 Vascular
R3 Vascular addresses the challenges of below-the-knee peripheral artery disease with their Magnitude® bioresorbable vascular scaffold. Metallic stents are currently being used in small vessels and are prone to crush and may make reintervention challenging during repeat procedures. This device delivers the strength and support of a traditional metallic stent while gradually dissolving as the vessel heals, restoring natural vascular function. Enhanced with a sirolimus drug eluting coating, Magnitude® combines anti-inflammatory benefits with robust mechanical support, potentially offering a safer and more effective solution for patients with critical limb ischemia.
SafeHeal
SafeHeal’s Colovac 2 device is disrupting traditional colorectal surgery by eliminating the need for patients to undergo temporary stoma bags which involve wearing external pouches to collect waste after cancer surgery of the colon. Colovac protects the surgical site, known as the anastomosis, allowing it to heal naturally without requiring a stoma. This innovation preserves patients’ dignity by sparing patients the physical and emotional discomfort of having a temporary stoma, as well as the potential complications that come with it, significantly improving patients’ quality of life. Once the healing is complete, the device is removed via a simple endoscopy, avoiding the need for a second surgery remove the stoma and enabling patients to return to their normal lives more quickly and comfortably.
TISSIUM
TISSIUM is transforming tissue reconstruction with its biomorphic programmable polymers and advanced delivery systems. The proprietary technology allows surgeons to operate effectively in challenging environments where traditional adhesives fail to perform. The polymers are designed to remain inert until activated by light, allowing proceduralists to carefully position the material before triggering adhesion. This approach ensures control, minimizing trauma and improves outcomes across procedures. Building on this core technology, TISSIUM addresses specific medical challenges while establishing a platform technology with potential for replication across numerous therapeutic applications. TISSIUM is currently advancing three key business verticals: nerve repair, hernia repair, and vascular sealants, demonstrating the versatility of TISSIUM’s platform.
VCD Medical
VCD Medical has developed a minimally invasive device that revolutionizes the treatment of varicose veins, a common condition that causes discomfort and pain. The Venous Closure Device uses bioabsorbable clips to close off problematic veins, providing a simpler and faster alternative to traditional treatments such as surgical stripping or thermal ablation. This device enables quick, outpatient-based procedures that significantly reduce recovery times and eliminate the need for more invasive surgeries. Patients benefit from a versatile, cost-effective solution that streamlines treatment and improves outcomes, making it easier to regain comfort and mobility.
Xeltis
Leveraging the Nobel Prize-winning supramolecular chemistry research of Professor Jean-Marie Lehn, Xeltis is developing a vascular restoration platform with implants that create living and durable vessels and valves. This implant utilizes Xeltis’ proprietary Endogenous Tissue Restoration (ETR) technology, which encourages the body to regenerate tissue within and around the implant. Over time, the implant is gradually absorbed, leaving behind a fully functional, natural vessel. With focus in three key areas of unmet need: vascular access, coronary arterial bypass surgery and pulmonary heart valve, Xeltis overcomes the limitations of current solutions, advancing care for millions of patients in need of cardiovascular replacements.
Sofinnova Partners
Sofinnova Partners is shaping the future of life sciences through its strategic investments in transformative healthcare and sustainability technologies. With over €2 billion under management, the firm backs innovative companies across early to late-stage development. By fostering advancements in areas like biotechnology, medical devices, and sustainability, they are driving innovation that improves lives and redefines the boundaries of science. Sofinnova Partners has achieved several notable MedTech exits, including the IPO of Shockwave Medical, a leader in intravascular lithotripsy technology, and Medtronic’s $700 million acquisition of CoreValve, a pioneer in transcatheter valve replacement systems showcasing its success in advancing innovative life sciences companies.
Sofinnova CrossOver Fund I
Key among its initiatives is the Sofinnova Crossover I fund, a €500 million late-stage healthcare fund supporting therapeutic and game-changing technologies led by experienced management teams.
MD Start III
Sofinnova also manages MD Start III, a €63 million MedTech acceleration fund that transforms medical concepts into successful therapeutic devices by providing seed funding and operational expertise.